| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and  therapeutic applications Nakamura A; Takeda SJ Biomed Biotechnol  2011[]; 2011 (ä): 184393Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disorder  characterized by muscle wasting which is caused by mutations in the DMD gene. The  DMD gene encodes the sarcolemmal protein dystrophin, and loss of dystrophin  causes muscle degeneration and necrosis. Thus far, therapies for this disorder  are unavailable. However, various therapeutic trials based on gene therapy, exon  skipping, cell therapy, read through therapy, or pharmaceutical agents have been  conducted extensively. In the development of therapy as well as elucidation of  pathogenesis in DMD, appropriate animal models are needed. Various animal models  of DMD have been identified, and mammalian (murine, canine, and feline) models  are indispensable for the examination of the mechanisms of pathogenesis and the  development of therapies. Here, we review the pathological features of DMD and  therapeutic applications, especially of exon skipping using antisense  oligonucleotides and gene therapies using viral vectors in murine and canine  models of DMD.|*Disease Models, Animal[MESH]|*Genetic Therapy[MESH]|Animals[MESH]|Dogs[MESH]|Humans[MESH]|Mice[MESH]|Muscular Dystrophy, Duchenne/genetics/*pathology/*therapy[MESH]
 |